Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Metadata
Title
Masa pancreática como presentación de recaída de cáncer de pulmón no microcítico
Authors
Pedro Pérez Segura
Carmen Perezagua Marín
Luis Ortega Medina
Eduardo Díaz-Rubio García
Publication date
01-06-2002
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 5/2002
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/BF02732514

Other articles of this Issue 5/2002

Clinical and Translational Oncology 5/2002 Go to the issue

Originales

A comparative study of HER2/neu amplification and overexpression using fluorescencein situ hybridization (FISH) and immunohistochemistry (IHC) in 101 breast cancer patients

Revisiones

Aspectos clínicos de la biología molecular del cáncer de próstata

Editorial

Prostate cancer: the great unknown

Originales

Factors involved in morbidity and mortality of total gastrectomy for gastric cancer

Notas Clínicas

A case of biliary adenofibroma of the liver causing elevated serum CA 19-9 levels

Sección Docente

Radioprotectors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits